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A B S T R A C T
Tartrazine is a food colour that activates the transcriptional function of the human oestrogen receptor alpha in
an in vitro cell model. Since oestrogens are cholestatic, we hypothesised tartrazine will cause periportal injury to
the liver in vivo. To test this hypothesis, tartrazine was initially administered systemically to mice resulting in a
periportal recruitment of inflammatory cells, increased serum alkaline phosphatase activity and mild periportal
fibrosis. To determine whether an oestrogenic effect may be a key event in this response, tartrazine, sulphonated
metabolites and a food additive contaminant were screened for their ability to interact with murine oestrogen
receptors. In all cases, there were no interactions as agonists or antagonists and further, no oestrogenicity was
observed with tartrazine in an in vivo uterine growth assay. To examine the relevance of the hepatic effects of
tartrazine to its use as a food additive, tartrazine was orally administered to transgenic NF-κB-Luc mice. Pre- and
concurrent oral treatment with alcohol was incorporated given its potential to promote gut permeability and
hepatic inflammation. Tartrazine alone induced NF- κB activities in the colon and liver but there was no
periportal recruitment of inflammatory cells or fibrosis. Tartrazine, its sulphonated metabolites and the
contaminant inhibited sulphotransferase activities in murine hepatic S9 extracts. Given the role of sulfotrans-
ferases in bile acid excretion, the initiating event giving rise to periportal inflammation and subsequent hepatic
pathology through systemic tartrazine exposure is therefore potentially associated an inhibition of bile acid
sulphation and excretion and not on oestrogen receptor-mediated transcriptional function. However, these
effects were restricted to systemic exposures to tartrazine and did not occur to any significant effect after oral
exposure.
1. Introduction
Many consumer products including food and personal care items
contain endocrine disrupting chemicals (EDCs) which may potentially
interfere with the endocrine system in animals and humans (Diamanti-
Kandarakis et al., 2009; Zoeller et al., 2012). A large number of EDCs
have oestrogenic properties in that they mimic the biological effects of
endogenous oestrogens. These chemicals are termed xenoestrogens and
they may modulate endogenous oestrogen activity by interfering with
endogenous oestrogen signalling or by disrupting synthesis, metabolism
and transport of oestrogens (Shanle and Xu, 2011). A common
mechanism in modulating oestrogen signalling is through interactions
of xenoestrogens with the nuclear oestrogen receptors (ERs), often
because they possess structural similarities to endogenous oestrogens
(McKenna and O'Malley, 2002).
The ERs belong to the superfamily of steroid hormone nuclear
receptors (Tsai and O'Malley, 1994; Hammes and Levin, 2007; see also
Nuclear Receptor Signalling Atlas https://www.nursa.org/nursa/index.
jsf). Two isoforms of the ER exist; the ERα (Green et al., 1986) and ERβ
(Mosselman et al., 1996; Kuiper et al., 1996; Moore et al., 1998). Both
ER isoforms are ligand-activated by oestrogens such as endogenous
17β-estradiol (E2) and mediate ER-regulated changes in gene expres-
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sion by interacting with specific DNA sequences (EREs) (Tsai and
O'Malley, 1994; Hammes and Levin, 2007). In order to screen for
chemicals having agonistic or antagonistic oestrogenic activity, a
human-based reporter gene assay was developed (Axon et al., 2012).
Employing this assay, the food colour tartrazine (also known as E 102)
was identified as an activator of the human ERα in vitro (Datta and
Lundin-Schiller, 2008; Axon et al., 2012).
The liver is a hormonal target for oestrogens via ERα (Ahlbory-
Dieker et al., 2009) and determines the circulating levels of oestrogens
via metabolic conversion of oestrogens to inactive products (Bondesson
et al., 2015; Tsuchiya et al., 2005; Ziegler et al., 2015). Thus, significant
inhibition of hepatic oestrogen metabolism through liver disease can
result in feminisation in men (Burra, 2013). The liver is also a target
organ for the toxic effects of high levels of oestrogens. Elevations in
circulating oestrogens are hepatotoxic due to a disruption of bile flow
and/or alteration in bile constituents (cholestasis) through a potential
combination of ERα-dependent suppression of transporter expression
(Yamamoto et al., 2006), ERα-dependent stimulation of canalicular
transporter endocytic internalization (Barosso et al., 2012) and/or
other signalling pathways such as GPR30 (Zucchetti et al., 2014).
Cholestasis leads to an accumulation of bile acids in the liver, which is
toxic and results in liver cell death (Woolbright and Jaeschke, 2012). In
susceptible individuals, the elevations in circulating oestrogens in
pregnancy or through use of contraceptives can be sufficient to lead
hepatic failure and death in the absence of liver transplantation (Ozkan
et al., 2015).
We hypothesised that tartrazine is a mouse ER activator and that if
sufficient intact food chemical is absorbed and reaches the liver, it
would have a cholestatic effect. We show that systemic exposure to
tartrazine through intraperitoneal administration resulted in a pathol-
ogy consistent with a cholestatic effect (although bile flow was not
examined). However, in vitro reporter gene screening assays with all
the known mouse ERs indicated that neither tartrazine, its sulphonated
metabolites nor a major sulphonated contaminant of the food colour
activated or antagonised any of the murine ER receptors. This was
supported by an in vivo mouse uterine growth bioassay with tartrazine
administered systemically. Oral exposure to tartrazine resulted in gut
and hepatic inflammation (based on activation of NF-κB transcriptional
function), but there was no evidence for any periportal inflammatory
cell recruitment or fibrosis via this route of exposure, and co-exposing
with ethanol to increase gut permeability to the food additive, inhibited
these effects. Since tartrazine, its 4 sulphonated metabolites and a
major sulphonated contaminant of the food additive inhibited dopa-
mine sulphotransferase in a dose-dependent manner in hepatic S9
extracts, the hepatic effects of systemic exposure to tartrazine may be
associated with an inhibition of bile acid sulphate conjugation.
However, this effect is unlikely to occur after oral exposure to
tartrazine.
2. Materials and methods
2.1. Materials
The mouse cholangiocyte cell line 603B was a gift from Dr Yedidya
Saiman, Mount Sinai School of Medicine, New York. The mouse
pancreatic epithelial cell line LTPA was originally obtained from the
American Type Culture Collection (ATCC, catalogue CRL-2389,
Manassas, Virginia). Tartrazine purity of 85% or greater – which meets
the EC specifications for its use as a food additive, E2 and ICI182780
were purchased from Sigma (Poole, UK). The tartrazine metabolites
sulphanilic acid (SA) [CAS 121-57-3] and 4-sulphopenylhydrazine
(SPH) [CAS 98-71-5] and the contaminant 5-oxo-1-(4-sulphophenyl)-
2-pyrazoline-3-carboxylic acid (OSPCA) [CAS 118-47-8, permitted at
up to 0.5% in tartrazine preparations when used as a food additive
according to EC and JECFA specifications] were purchased from Sigma
(Poole, UK). The tartrazine metabolites sulphanilic acid N-acetate (SA-
NAc) [CAS 121-62-0] and 1-(4-sulphophenyl)-3-carboxy-4-amino-5-
pyrazolone (SCAP) [CAS 2508-84-1] were purchased from Santa Cruz
Biotechnology (Dallas, Texas, USA) and custom synthesised by An-gene
(Hong Kong) respectively. Analytical data for SCAP is provided in
Supplementary Fig. 1.
2.2. Animal studies
C57Bl/6 wild type (wt) mice were purchased from Charles River
(Kent, UK). Transgenic NF-κB-Luciferase (tg) mice (bearing a transgene
composed of three NF- B sites from the Ig light chain promoter coupled
to the gene encoding firefly luciferase) were originally obtained from Dr
Harald Carlsen (Oslo University, Norway) and were generated and
genotyped as previously described (Wallace et al., 2010). All animals
had free access to food and water and conditions were kept on a 12 h
light/12 h dark cycle at 47% relative humidity at 23 °C ± 1 °C. All
experiments were performed under a UK Home Office licence with
Local Ethics Committee approval.
2.2.1. Systemic exposure to tartrazine in adult mice
To investigate the effects of direct tartrazine exposure, male 12
week old mice were dosed with tartrazine at 50 mg/kg bw/day
[dissolved in 137 mM NaCl, 2.7 mM KCl, 10 mM phosphate pH 7.4
(PBS)] via 5 intraperitoneal injections per week for 2 weeks before
termination 24 h after the last administration. Control mice were
administered with the PBS vehicle alone. Mice were exposed to E2
[prepared in ethanol:olive oil (1:20, v/v)] by intraperitoneal injection
at a dose of 0.5 mg/kg bw/day for 3 consecutive days before termina-
tion 24 h after the last administration. Control mice were administered
with ethanol:olive oil (1:20, v/v)] vehicle alone.
2.2.2. In vivo uterine growth bioassay
To test for mouse ERα activation in vivo, 19 day old female wt mice
were treated with oestrogen or potential xenooestrogens by daily
intraperitoneal injection on 4 consecutive days. Compounds were
prepared in PBS or ethanol:olive oil (1:20, v/v) solvent vehicle with
control mice administered solvent vehicle alone. On day 5, mice were
culled and uteri removed and relative wet weight determined.
2.2.3. Oral exposure to tartrazine in adult mice, effect of alcohol
To investigate effects of oral tartrazine exposure, male adult wt and
tg mice were pre-treated with 3 g ethanol per kg bodyweight from a
20% (v/v) ethanol solution twice daily by oral gavage for 14 days to
increase gut permeability and/or alter the gut microbiota (Kirpich
et al., 2012; Szabo, 2015). The control group was pre-dosed with 6.32 g
dextrose (Sigma) per kg bodyweight from a 0.33 g/ml dextrose solution
to control for the calorific content of ethanol. Following the 14-day pre-
treatment period, mice were administered 50 mg tartrazine per kg
bodyweight from a 2.6 mg/ml stock in either 20% (v/v) ethanol
solution or in 0.33 g/ml dextrose solution by oral gavage twice daily
for 10 consecutive weeks. Mice in the control groups were dosed with
ethanol or dextrose solution alone. Body weights were measured once a
week. Tg mice were imaged for inflammation by live in vivo imaging on
an IVIS spectrum (Caliper Life Sciences) essentially as previously
outlined (Wallace et al., 2010). D-luciferin was obtained from Synchem
(Altenburg, Germany).
2.3. Cell line culture
603B cells were cultured in low glucose Dulbecco’s Modified Eagles
Medium (Sigma, Dorset, UK), supplemented with 10% (v/v) foetal
bovine serum (Sigma) and 80 U/ml of penicillin and streptomycin.
LTPA cells were cultured in the above medium further supplemented
with 0.1 mM non-essential amino acids (Gibco, Life technologies,
Paisley, UK) and 1 mM sodium pyruvate (Gibco, Life technologies).
All cell lines were maintained in a humidified atmosphere at 37 °C in
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5% CO2 in air.
2.4. Transfection and reporter gene assays
The mERα, mERβv1 and mERβv2 cDNA sequences were previously
cloned and their transcriptional functionality examined in cholangio-
cyte cell lines (Meyer et al., 2017). Note, that previous work identified
that the LTPA cell line combined with the 3×ERE TATA Luc reporter
gene construct (originally constructed by Donald McDonnell and
obtained via Adgene plasmid # 11354) are optimal for identifying
mERα-dependent transcriptional activation whereas the 603B cells
coupled with the (ERE)3-pGL3promoter construct is optimal for
identifying ERβ-dependent transcriptional activation (Meyer et al.,
2017). In all cases, cells were transiently transfected in 24-well plates
with 0.25 μg total DNA per well (pcDNA3.1 expression vector encoding
the mouse ERα, ERβv1 or ERβv2 proteins essentially as previously
described (Meyer et al., 2017), an oestrogen-responsive luciferase
reporter gene construct and a control plasmid (RL-TK) encoding the
Renilla luciferase protein under the control of a constitutive thymidine
kinase promoter to control for transfection efficiency between wells.
Cells were transfected with constructs at a ratio of 6:6:1 using Effectene
reagent (Qiagen, Manchester, UK), according to the manufacturer’s
instructions. Twenty four hours after transfection, cells were, where
applicable, pre-treated with the pure ER antagonist ICI182780 for 6 h
before being treated with oestrogens or potential xenoestrogens from
1000-fold concentrated stocks in DMSO or PBS. Control cells were
treated with 0.1% v/v DMSO or PBS. The human ERβ expression
construct pcDNA Flag ERβ originally cloned by Zhang et al. (2010) and
was obtained from Adgene (Adgene plasmid # 35562). To examine
potential activation of the human ERβ, ER negative HEK293 cells were
Fig. 1. Systemic exposure to tartrazine results in a periportal inflammatory cell recruitment in mice. Adult male C57Bl/6 mice were administered either tartrazine (T, 4 animals),
E2 (4 animals) or relevant vehicle control (PBS for tratrazine, 3 animals; 1:19 ethanol:olive oil (v/v) for E2, 4 animals) by 10 daily intraperitoneal injections over 14 days. A, serum ALP,
*significantly different activity versus vehicle control using the Student’s t-test (two tailed), p > 0.95. B, H & E-stained liver sections from animals treated as indicated, typical views
chosen. C, quantification of portal tract inflammatory cells, *significantly different number of portal tract cells versus vehicle control using the Student’s t-test (two tailed), p > 0.95
based on at least 10 randomly selected portal tracts per animal. D, sirius red-stained liver sections from animals treated as indicated, typical views chosen. E, quantification of sirius red
positive stained area, *significantly different activity versus vehicle control using the Student’s t-test (two tailed), p > 0.95.
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transiently transfected in 24-well plates with 0.32 μg total DNA per well
– pcDNA Flag ERβ, (ERE)3-pGL3promoter (Axon et al., 2012) and the
RL-TK control plasmid at a ratio of 6:6:1 respectively) using calcium
phosphate. Twenty-four hours after transfection, cells were treated with
tartrazine, its metabolites and the contaminant from 1000-fold con-
centrated stocks in DMSO or PBS. Following exposure for 24 h,
luciferase activities were determined using a Dual-Glo luciferase assay
kit (Promega).
2.5. Immunohistochemistry
Livers were fixed in 10% buffered formalin in PBS for 24 h before
paraffin embedding and sectioning at 4 μm. Tissue sections were
stained with Haematoxylin and Eosin (H & E) or sirius red as previously
described (Marek et al., 2005).
2.6. Clinical chemistry
Serum samples were prepared from blood by centrifugation for
determination of alkaline phosphatase (ALP) serum enzyme levels
(Alkaline Phosphatase Assay Kit (Fluorometric), Abcam) according to
the manufacturer’s instructions. Alanine aminotransferase (ALT) serum
levels were measured as previously described (Probert et al., 2014).
2.7. Liver S9 preparation and sulphotransferase assays
Liver S9 extracts were prepared and sulphotransferase assays
performed using 35S 3′-phosphoadenosine-5′-phosphosulfate as pre-
viously described (Probert et al., 2016).
3. Results
3.1. Systemic exposure to tartrazine caused a mild cholestatic liver injury in
mice
To investigate the effects that direct exposure to tartrazine may
have on the liver, tartrazine was administered to mice by intraperito-
neal injection at 50 mg/kg bw/day, 6.7 times the current EU ADI (EFSA
Fig. 1. (continued)
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Panel on Food Additives and Nutrient Sources added to Food (ANS),
2009). Male mice were chosen for this study since the mouse menstrual
cycle is short relative to the time over which the study was performed.
Since males have a lower, and more consistent, level of circulating
oestrogen, it was considered that a study in males would more likely
detect any oestrogenic effect of the administered compounds.
Fig. 1A demonstrates that there was an increase in serum alkaline
phosphatase (ALP) levels following treatment with either E2 or
tartrazine. Fig. 1B and C indicate that treatment with either E2 or
tartrazine resulted in an increase in inflammatory cells in the portal
tract region in the liver and an increase in collagen deposition (fibrosis)
was observed (Fig. 1D and E).
These data suggest that direct exposure to both oestrogen (E2) and
tartrazine resulted in periportal inflammation and mild fibrosis.
3.2. Tartrazine, its major gut-derived and endogenous metabolites and a
contaminant of the food additive do not activate the murine oestrogen
receptors
Despite intolerance reactions in man such as urticaria (Rajan et al.,
2014), estimated to be around 0.12% of the population (Elhkim et al.,
2007), data regarding the metabolism of tartrazine in experimental
animals and man is limited.
Tartrazine is predominantly metabolised to sulphanilic acid (which
may be further N-acetylated) and 4-sulphophenylhydrazine in the gut.
These metabolites are absorbed and appear in the urine and only a
minor proportion of any oral dose of tartrazine is absorbed intact (Jones
et al., 1964; Roxon et al., 1966; Ryan et al., 1969a,b). The enzymatic
azo reduction of tartrazine has been shown to be dependent on gut
microorganisms (Roxon et al., 1967; Ryan et al., 1969a,b). After
intraperitoneal administration of 2.4 mg/kg bw of 14C-tartrazine,
between 64 and 96% of the dose was recovered unchanged in urine
within 24 h in rats and rabbits and no other products were reported. At
higher doses, free and conjugated sulphanilic acid begin to be detected
in the urine (Jones et al., 1964). Based on these data, the catabolism of
tartrazine is summarised in Supplementary Fig. 2.
Fig. 2A demonstrates that E2 activated the mERα, resulting in trans-
activation of reporter gene expression at concentrations as low as 10pM
and in a dose-dependent manner, whereas there was no evidence for
trans-activation with tartrazine or its gut-derived and endogenous
metabolites or a contaminant of the food additive at concentrations
up to 100 μM. Fig. 2B further indicates these compounds also did not
inhibit E2-dependent trans-activation of reporter gene expression,
suggesting that these compounds are not ERα antagonists.
Fig. 3A shows that E2 activated the mERβv1 resulting in trans-
activation of reporter gene expression at concentrations as low as 1 nM
and in a dose-dependent manner, whereas there was no evidence for
trans-activation with tartrazine or its gut-derived and endogenous
metabolites or a contaminant of the food additive at concentrations
up to 100 μM. Fig. 3B further indicates these compounds also did not
inhibit E2-dependent trans-activation of reporter gene expression,
suggesting that these compounds are not ERβv1 antagonists.
Previous work by this lab has shown that the mouse ERβv2 is
constitutively active and that pre-treatment with ICI182780 and wash
out de-activates transcriptional activity and renders the receptor
amenable to activation by subsequent exposure to oestrogens such as
E2 or ethinyloestradiol (Meyer et al., 2017). Fig. 4A demonstrates that
E2 activates the mERβv2 (after de-activation), resulting in trans-
activation of reporter gene expression at concentrations as low as at
least 100pM and in a dose-dependent manner, whereas there was no
evidence for trans-activation or antagonism with tartrazine or its gut-
derived and endogenous metabolites or a contaminant of the food
additive at concentrations up to 100 μM. Fig. 4B further indicates that
these compounds did not inhibit E2-dependent (1 nM) trans-activation
of reporter gene expression, in contrast to ICI182780, indicating that
tartrazine, its gut-derived and endogenous metabolites or a contami-
nant of the food additive are not antagonists of the mERβv2. Supple-
mentary Fig. 3 indicates that tartrazine – but not its gut-derived and
endogenous metabolites or a contaminant of the food additive –
activates the human ERβ although only significantly at concentrations
of tartrazine in excess of around 500 μM.
These data therefore suggest that neither tartrazine, its gut-derived
and endogenous metabolites nor a contaminant of the food additive
interact with the murine ERs.
3.3. Tartrazine administered systemically is not a mERa activator in vivo
The major biological function of oestrogens in women is to regulate
the variety of physiological changes associated with female reproduc-
tion (in sexually mature women) (Bondesson et al., 2015). These
changes are most physiologically overt via developmental changes in
reproductive-relevant tissues such as the uterus and breast and an
established assay for these effects in vivo is through determination of
uterine wet weight changes on exposure to oestrogens (Reel et al.,
1996).
Examination of mouse ERα activation in vivo by mouse uterine
bioassay shows that administration of E2 and the xenooestrogen
pesticide – methoxychlor – resulted in an increase in uterine wet
weight. In contrast, neither dose levels of tartrazine – 0.5 mg/kg bw/
day (0.067 fold of the ADI) nor 50 mg/kg bw/day (6.7 fold of the ADI) –
gave rise to a change in uterine wet weight (Fig. 5A and B). Admin-
istration of sunset yellow, which was also identified as a hERα activator
in vitro (Axon et al., 2012), also had no effect on uterine wet weight
(Fig. 5A and B). Note that E2, methoxychlor and butylparaben were
administered in an ethanol: olive oil vehicle whereas all other
compounds were soluble in PBS. Moderate ethanol consumption has
been shown to increase circulating oestrogen levels (Gill, 2000) and to
stimulate oestrogen signalling (Fan et al., 2000) which may account for
the mild oestrogenic effect of the ethanol:olive oil vehicle commonly
used by others in animal studies involving steroid dosing (Sawada et al.,
2000; Evans et al., 2002) versus PBS-dosed mice.
These data indicate that systemic exposure to tartrazine at levels
that exceed those likely to occur through oral exposure and absorption,
did not result in any observed oestrogenic effect in vivo in mice.
3.4. Oral exposure to tartrazine caused gut and liver inflammation without
cholestatic liver injury in mice
Tartrazine is a widely used colour and exposure in man is primarily
via oral exposure in food. Therefore, to determine the toxicological
relevance of the hepatic effects observed with tartrazine exposure after
intraperitoneal exposure to its use as a food additive, mice were orally
exposed to tartrazine at 50 mg/kg bw/day for up to 10 weeks. Since
tartrazine is often added to alcoholic drinks; alcohol is known to affect
the gut microbiota and/or gut permeability and that these effects are a
major driver of adverse hepatic effects to alcohol in animal models
(Kirpich et al., 2012; Szabo, 2015; Scarpellini et al., 2016), the effects of
co-exposure to alcohol and tartrazine was also examined. Mice were
pre-treated with ethanol or dextrose (as a control for the energy content
of ethanol) for 14 days prior to administration of tartrazine and/or
ethanol for 10 weeks.
IVIS imaging of Tg mice for inflammatory responses via increases in
NF-kB luciferase expression demonstrated that there was a significant
increase in abdominal region inflammation (corresponding to the
gastrointestinal tract) by 10 and 12 weeks of the study, and by 12
weeks in the hepatic region in response to tartrazine treatment (Fig. 6A
and B). Ethanol treatment did not result in any apparent inflammatory
effects and inhibited the inflammation associated with tartrazine
exposure (Fig. 6A and B).
Examination of individual organs at the end of the study confirmed
that the inflammation observed via live animal imaging was associated
with the liver and gastrointestinal tract (Fig. 6C). Of note, the
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inflammation associated with the gastrointestinal tract was located at
the colon (Fig. 6C). At 12 weeks, analysis of serum liver enzyme
activities suggested that there was no evidence for periportal liver
injury on the basis of serum ALP levels (Fig. 6D). Histological
examination for inflammatory cells around the periportal regions of
the liver lobule and fibrosis – as observed after treatment with
oestrogens – indicated that all treatment groups were similar to control
treated animals (data not shown). A three-fold increase in serum ALT
compared to control animals was observed in response to ethanol
treatment [although not statistically significant, is typical of the
increases observed in other studies (Abdelmegeed et al., 2013; Wang
et al., 2015; Zhang et al., 2016) was the only evidence of mild
hepatocellular injury (Fig. 6E).
These data therefore indicate that oral administration of tartrazine
at 6.7 fold the current ADI over 10 weeks resulted in a mild
inflammatory response in the gut and liver, but that this was not
associated with any significant liver injury. Co-treatment with ethanol
reduced the inflammatory response to tartrazine.
Fig. 2. Tartrazine, its sulphonated metabolites or major sulphonated contaminant are neither agonists nor antagonists of the mouse ERα. Luciferase reporter gene (3XERE
TATA Luc) assay in LTPA cells co-transfected with a pcDNA3.1 expression construct encoding the mERα. A, cells were treated with E2, tartrazine (T) or its sulphonated metabolites (SA,
sulphanilic acid; SA-NAc, sulphanilic acid N-acetate; SCAP, 1-(4-sulphophenyl)-3-carboxy-4-amino-5-pyrazolone; SPH, sulphophenylhydrazine) or major sulphonated contaminant 5-oxo-
1-(4-sulphophenyl)-2-pyrazoline-3-carboxylic acid (OSPCA); at the indicated concentrations for 24 h. Data are the mean and standard deviation luciferase activity from 3 separate
determinations from the same experiment, typical of at least 3 separate experiments. Data are expressed as fold change versus vehicle-treated cells (vehicle: 0.1% v/v DMSO for E2 and
tartrazine or 0.1% (v/v) PBS for SA, SPH, SCAP, SA-NAc and OSPCA). *Significant increase (p > 0.95) over vehicle treated cells using one-way ANOVA with Dunnett’s post-hoc test. B,
cells were pre-treated with 100 nM ICI182780 for 6 h followed by treatment with ICI182780, tartrazine or metabolites in the presence of 1 nM E2 for 24 h. Data are the mean and
standard deviation luciferase activity from 3 separate determinations from the same experiment, typical of at least 3 separate experiments and expressed in fold change versus vehicle-
treated cells (vehicle: 0.1% v/v DMSO for E2 and tartrazine or 0.1% v/v PBS for SA, SPH, SCAP, SA-NAc and OSPCA). *Significant increase (p > 0.95) over cells treated with vehicle only
using Student’s T-test (two-tailed). #Significant decrease (p > 0.95) over cells treated with 1 nM E2 in the absence of ICI182780 using One-way ANOVA with Dunnett’s post-hoc test.
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3.5. Tartrazine, its major gut-derived and endogenous metabolites and a
contaminant of the food additive inhibit murine hepatic sulphotransferases
Tartrazine has been reported to be an inhibitor of hepatic sulpho-
transferases using several substrates and an S9 preparation of human
liver, the most potent inhibition (94 ± 3% inhibition at 6.7 μM
tartrazine) observed when dopamine was the substrate (Bamforth
et al., 1993). The effect of tartrazine, its sulphonated metabolites and
a major sulphonated contaminant of the food additive on mouse hepatic
S9 sulphation was therefore examined. Fig. 7A demonstrates that
tartrazine, all 4 metabolites and the major contaminant of the food
additive inhibited dopamine sulphotransferase in a dose-dependent
manner in murine hepatic S9 extracts. However, significant inhibition
was not seen until concentrations greater than 100 μM. SCAP and
OSPCA appeared to be the most potent inhibitors of murine dopamine
sulfotransferase activity with significant inhibition observed at 500 μM
(Fig. 7A). Tartrazine, its sulphonated metabolites and a major sulpho-
nated contaminant of the food additive also inhibited oestrone sulpha-
Fig. 3. Tartrazine, its sulphonated metabolites or major sulphonated contaminant are neither agonists nor antagonists of the mouse ERβ variant 1. Luciferase reporter gene
((ERE)3-pGL3promotor) assay in 603B cells co-transfected with a pcDNA3.1 expression construct encoding the mouse ERβ variant 1. A, cells were treated with E2, tartrazine or its
sulphonated metabolites or major sulphonated contaminant at the indicated concentrations for 24 h. Data are the mean and standard deviation luciferase activity from 3 separate
determinations from the same experiment, typical of at least 3 separate experiments. Data are expressed in fold change versus vehicle-treated cells (vehicle: 0.1% v/v DMSO for E2 and
tartrazine or 0.1% v/v PBS for SA, SPH, SCAP, SA-NAc and OSPCA). *Significant increase (p > 0.95) over cells treated with the equivalent vehicle using One-way ANOVA with Dunnett’s
post-hoc test. B, cells were pre-treated with 100 nM ICI182780, followed by treatment with ICI182780, tartrazine, sulphonated metabolites or major sulphonated contaminant with the
addition of 1 nM E2 for 24 h. Data are the mean and standard deviation luciferase activity from 3 separate determinations from the same experiment, typical of at least 3 separate
experiments and expressed in fold change versus vehicle-treated cells (vehicle: 0.1% v/v DMSO for E2 and tartrazine or 0.1% v/v PBS for SA, SPH, SCAP, SA-NAc and OSPCA).
*Significant increase (p > 0.95) over cells treated with vehicle only using Student’s T-test (two-tailed). #Significant decrease (p > 0.95) over cells treated with 1 nM E2 in the absence
of ICI182780 using one-way ANOVA with Dunnett’s post-hoc test.
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tion in a similar manner (Fig. 6B) as well as sulphation of dehydroe-
piandrosterone, ρ-nitrophenol or 4-methylumbelliferone in murine S9
extracts (data not shown) suggesting that the inhibitory action is via a
competition with PAPS for sulphotransferases.
4. Discussion
Tartrazine (E 102) is a sulphonated dye used as an additive in food.
Tartrazine is also used in some cosmetics and other products. It is
known to elicit intolerance reactions in a small fraction of the exposed
population and that sensitive individuals may react to tartrazine at dose
levels within the ADI (EFSA Panel on Food Additives and Nutrient
Sources added to Food (ANS), 2009).
Since tartrazine has been shown to activate the human ERα in in
vitro cell model test systems by several independent labs (Datta and
Lundin-Schiller, 2008; Axon et al., 2012) and oestrogens are cholestatic
in vivo (Ozkan et al., 2015), we initially hypothesised that tartrazine
will have cholestatic effects in vivo via an interaction with the ERα. We
Fig. 4. Tartrazine, its sulphonated metabolites or major sulphonated contaminant are neither agonists nor antagonists of the mouse ERβ variant 2. Luciferase reporter gene
((ERE)3-pGL3promotor) assay in 603B cells co-transfected with a pcDNA3.1 expression construct encoding the mouse ERβ variant 2. A, constitutively activate mouse ERβ variant 2 was
de-activated with 100 nM ICI182780 for 6 h followed by several wash steps with sterile PBS. Cells were then treated with E2, tartrazine or its sulphonated metabolites or major
sulphonated contaminant at the indicated concentrations for 24 h. Data are the mean and standard deviation luciferase activity from 3 separate determinations from the same experiment,
typical of at least 3 separate experiments. Data are expressed in fold change versus vehicle-treated cells (vehicle: 0.1% v/v DMSO for E2 and tartrazine or 0.1% v/v PBS for SA, SPH, SCAP,
SA-NAc and OSPCA). *Significant increase (p > 0.95) over cells treated with the equivalent vehicle using one-way ANOVA with Dunnett’s post-hoc test. B, cells were pre-treated with
100 nM ICI182780 for 6 h followed by treatment with ICI182780, tartrazine, sulphonated metabolites or major sulphonated contaminant with the addition of 1 nM E2 for 24 h. Data are
the mean and standard deviation luciferase activity from 3 separate determinations from the same experiment, typical of at least 3 separate experiments and expressed in fold change
versus vehicle-treated cells (vehicle: 0.1% v/v DMSO for E2 and tartrazine or 0.1% v/v PBS for SA, SPH, SCAP, SA-NAc and OSPCA). *Significant increase (p > 0.95) over cells treated
with vehicle only using Student’s T-test (two-tailed). #Significant decrease (p < 0.95) over cells treated with 1 nM E2 in the absence of ICI182780 using one-way ANOVA with Dunnett’s
post-hoc test.
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demonstrate in this paper that tartrazine, when administered intraper-
itoneally at a dose (in excess of the ADI of 7.5 mg/kg bw/day) of
50 mg/kg bw/day (10 daily doses over 14 days) resulted in periportal
inflammation and mild injury suggestive of a cholestatic effect in mice.
However, to confirm a cholestatic effect for tartrazine, bile flow and/or
reductions in transporter-mediated efflux of bile constituents would be
required. Acute, high levels of systemic oestrogen exposure (e.g. 100-
fold normal circulating levels) leads to cholestatic effects in the liver,
accompanied by portal tract inflammation and a fibrotic reaction (Axon
et al., 2010). Intraperitoneal administration of tartrazine to mice
resulted in qualitatively similar hepatic pathological effects to that
seen after acute oestrogen administration, therefore we initially pro-
posed that these effects could be associated with activation of murine
ERs, alterations in hepatic transporter expression and subsequent
cholestatic liver injury. However, we demonstrate that tartrazine, 4 of
its sulphonated metabolites and a major sulphonated contaminant of
the food additive lack murine ERα agonist or antagonist activities in in
vitro cell based assays. These observations were supported by an
absence of any effect on uterine growth in mice by tartrazine, in
contrast to detectable increases after oestrogen or methoxychlor (a
xenoestrogen insecticide) administration. Furthermore, there have been
no indications for an adverse effect on reproduction or development
with tartrazine (EFSA Panel on Food Additives and Nutrient Sources
added to Food (ANS), 2009). In studies by Tanaka (2006) and Tanaka
et al. (2008), deleterious effects on reproductive parameters were not
demonstrated up to and including dose levels of 773 and 1225 mg
tartrazine/kg bw/day for dietary supplementation for males and
females, respectively, the highest dose levels tested.
The ability of tartrazine and its metabolites/major contaminant to
interact with the related ERβ was also examined. The ERβ is expressed
at low levels in normal human and rodent liver (Alvaro et al., 2004,
2006; Meyer et al., 2017). However, in a liver disease setting, the levels
of ERβ expression in cholangiocytes is markedly increased and is
thought to impact on the proliferation of bile ductules that occurs in
cholestasis (Alvaro et al., 2006; Marzioni et al., 2012). In our hands, we
also found that tartrazine, 4 of its sulphonated metabolites and a major
sulphonated contaminant of the food additive lack murine ERβ variant
1 or variant 2 agonist or antagonist activities in in vitro cell based
assays.
Since tartrazine, when used as a food additive, is mostly hydrolysed
in the gastrointestinal tract and not significantly absorbed intact, the
relevance of a hepatic effects of tartrazine after intraperitoneal admin-
Fig. 5. Tartrazine lacks an uterotrophic effect in mice in vivo. Nineteen day old female C57Bl6 mice were administered the indicated compound by single intraperitoneal injection for
four consecutive days before study termination and excision of uteri on day 5. A, photomicrograph of typical uteri at termination demonstrating physiological effect of treatments. B,
mean relative wet weight of uteri at study termination. Data are the mean and standard deviation of at least 4 animals/group, *significantly different wet weight versus vehicle control
using the Student’s t-test (two tailed), p > 0.95.
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istration in man is likely to be low, unless these hepatic effects can also
be attributed to any metabolites of tartrazine that are absorbed. To test
the food additive relevance of these observations, tartrazine was orally
administered to mice and the effect of pre- and concurrent oral
treatment with alcohol incorporated into the study since tartrazine
may be consumed with alcohol and because alcohol may promote both
gut permeability and hepatic inflammation. Although tartrazine alone
induced inflammation in the colon and liver, there was no evidence of a
periportal inflammatory cell recruitment and subsequent fibrosis. These
data therefore indicate that oral administration of tartrazine at 6.7 fold
the current ADI over 10 weeks resulted in a mild inflammatory response
in the gut and liver, but that this was not associated with any significant
Fig. 6. Oral exposure to tartrazine results in gastrointestinal and hepatic inflammation without leading to cholestasis. Adult male C57Bl/6 Tg(NF-kB) and wild type mice were
initially orally administered twice daily with either ethanol or dextrose for 2 weeks and then additionally with or without tartrazine for a further 10 weeks as outlined in methods section.
Mice in the control groups were dosed with ethanol or dextrose solution alone. A, IVIS images of Tg(NF-kB) mice at the indicated times after initial treatment. B, Integrated photon
emission analysis of light emission profiles of the hepatic and abdominal regions of live Tg(NF-kB) animal images and the indicated times after initial treatment, data are the mean and
standard deviation of at least 3 animals/group, *significantly different from control vehicle treated mice using the Student’s t-test, two-tailed, p > 0.95. C, IVIS images of Tg(NF-kB)
mouse organs at termination of the study (12 weeks after study initiation). D, Integrated photon emission analysis of light emission profiles of the organs from Tg(NF-kB) animal images at
termination of the study (12 weeks after study initiation), data are the mean and standard deviation of at least 3 animals/group, *significantly different from control vehicle treated mice
using the Student’s t-test, two-tailed, p > 0.95. E, serum ALP (left panel) and ALT (right panel) at termination of the study (12 weeks after study initiation), data are the mean and
standard deviation of at least 3 animals/group, *significantly different from control vehicle treated mice using the Student’s t-test, two-tailed, p > 0.95.
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liver injury. Co-treatment with ethanol reduced the inflammatory
response to tartrazine. These effects occurred in the absence of any
interaction with murine oestrogen receptors.
The pathological effects of oestrogens in the liver have been
attributed to either an ERα-dependent suppression of transporter
expression (Yamamoto et al., 2006) and/or stimulation of canalicular
transporter endocytic internalization (Barosso et al., 2012) and/or to a
saturation of hepatic oestrogen metabolism and transport that leads to a
disruption in bile acid secretion or cholestasis (Stieger et al., 2000) and
subsequent portal tract toxicity. Additional complexities include a role
also for other signalling pathways such as GPR30 (Zucchetti et al.,
2014). Since some bile acids undergo sulphation prior to secretion and
excretion (Alnouti, 2009), the effects of tartrazine on hepatic sulpho-
transferase activities were examined. We demonstrate that tartrazine –
and for the first time – 4 of its sulphonated metabolites and a major
sulphonated contaminant of the food additive inhibited both dopamine
and oestrone sulphotransferases in a dose-dependent manner in hepatic
S9 extracts.
In man, under normal (e.g. non cholestatic) conditions, non-
sulphated bile acids are sequestered within the enterohepatic circula-
tion (Alnouti, 2009). Sulphation of bile acids at the 3 position by
SULT2A1 is a major route of bile acid elimination, with the majority
entering the systemic circulation and excreted by the kidneys into the
urine (Alnouti, 2009). Sulphated bile acids reaching the gut are
resistant to metabolism by the microbiota and eventual de-conjugation
and metabolism to more toxic secondary bile acids occurs sufficiently
late in its passage through the gastrointestinal tract that much of the
bile acid is eliminated in the faeces. Thus, bile acid sulphation is a
Fig. 6. (continued)
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mechanism for bile acid elimination in man (Alnouti, 2009). The
apparent inflammatory effects observed in the gastrointestinal tract
and liver may be associated with a modulation of bile acid sulphation
and excretion. However, given that the doses of tartrazine employed in
these studies were 6.7 fold in excess of the current ADI, the absence of
any periportal inflammatory cell recruitment and fibrosis effects after
oral exposure, even on a background of chronic high levels of exposure
to alcohol, is unlikely to be of toxicological relevance in respect of its
use as a food additive. In rats and mice, sulphation of bile acids is a
minor metabolic route and renal excretion of bile acids is more reliant
on hydroxylation at the 6 position (Alnouti, 2009). An inhibition of
sulphation by E2 or tartrazine in murine liver is therefore likely to have
a less significant impact on bile acid excretion and toxicity in mice than
man and therefore, the histopathological effects observed in mice after
of tartrazine exposure could under-estimate the potential hepatic effects
in man. Polymorphisms – including copy number variations (Schulze
et al., 2013) – in human SULT2A1 are known (García-Anguita et al.,
2013) may also result in increased sensitivity to tartrazine in man.
There may therefore be a potential for tartrazine to alter bile home-
ostasis in man given its potential additional ability to activate the
human ERα, although more studies will be required to determine if this
could be the case.
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